Novartis meningitis B vaccine Bexsero OK'd in US
This article was originally published in Scrip
Executive Summary
The FDA on 23 January cleared the way for Novartis to market its much-anticipated meningitis B vaccine Bexsero, which is approved for use in Americans 10-25 years.